DMC Biotechnologies Raises $18 Million in Financing

• DMC Biotechnologies secured $18 million in financing on October 26, 2026, to expand its health ingredients business.
• The US-based company develops high-purity bioactive ingredients through precision fermentation.
• Inceptional Partners and Sofinnova Partners co-led the financing, with participation from First Bight Ventures.
• Existing investors Cibus Capital and Capricorn Partners also participated.
• Proceeds will accelerate commercialization of the KeyPura ingredient portfolio, support customer adoption and fund development of additional health ingredients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DMC Biotechnologies Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.